Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.
Lin-Yan Zeng,Jiang-Shan Lian,Jian-Yang Chen,Hong-Yu Jia,Yi-Min Zhang,Dai-Rong Xiang,Liang Yu,Jian-Hua Hu,Ying-Feng Lu,Lin Zheng,Lan-Juan Li,Yi-Da Yang
DOI: https://doi.org/10.3748/wjg.v20.i27.9178
IF: 5.374
2014-01-01
World Journal of Gastroenterology
Abstract:AIM: To determine the baseline hepatitis B surface antigen (HBsAg) levels during the different phases of chronic hepatitis B (CHB) patients in China. METHODS: Six hundred and twenty-three hepatitis B virus or un-infected patients not receiving antiviral therapy were analyzed in a cross-sectional study. The CHB patients were classified into five phases: immune-tolerant (IT, n = 108), immune-clearance (IC, n = 161), hepatitis B e antigen negative hepatitis (ENH, n = 149), low-replicative (LR, n = 135), and liver cirrhosis (LC, n = 70). HBsAg was quantified (Abbott ARCHITECT assay) and correlated with hepatitis B virus (HBV) DNA, and serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) in each phase of CHB was also determined. RESULTS: Median HBsAg titers were different in each phase of CHB (P < 0.001): IT (4.85 log(10) IU/mL), IC (4.36 log(10) IU/mL), ENH (2.95 log(10) IU/mL), LR (3.18 log(10) IU/mL) and LC (2.69 log(10) IU/mL). HBsAg titers were highest in the IT phase and lowest in the LC phase. Serum HBsAg titers showed a strong correlation with HBV viral load in the IC phase (r = 0.683, P < 0.001). No correlation between serum HBsAg level and ALT/AST was observed. CONCLUSION: The mean baseline HBsAg levels differ significantly during the five phases of CHB, providing evidence on the natural history of HBV infection. HBsAg quantification may predict the effects of immunemodulator or oral nucleos(t) ide analogue therapy. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.